Back
OncoCyte 10K Form
Sell
37
OCX
OncoCyte
Last Price:
$3.00
Seasonality Move:
-2.87%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-04-28 | 10K | OCX/OncoCyte Annual |
| 2020-03-26 | 10K | OCX/OncoCyte Annual |
| 2019-11-14 | 10Q | OCX/OncoCyte Quarterly |
| 2019-08-14 | 10Q | OCX/OncoCyte Quarterly |
| 2019-05-14 | 10Q | OCX/OncoCyte Quarterly |
| 2019-04-30 | 10K | OCX/OncoCyte Annual |
Receive OCX News And Ratings
See the #1 stock for the next 7 days that we like better than OCX
OCX Financial Statistics
Sales & Book Value
| Annual Sales: | $1.9M |
|---|---|
| Cash Flow: | $-5.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.70 |
| Price / Book: | 5.77 |
Profitability
| EPS (TTM): | -4.40000 |
|---|---|
| Net Income (TTM): | $-60.7M |
| Gross Margin: | $740K |
| Return on Equity: | -581.11% |
| Return on Assets: | -93.08% |
OncoCyte Earnings Forecast
Key OncoCyte Financial Ratios
-
The Gross Profit Margin over the past 6 years for OCX is 39.34%.
-
The Selling, General & Administrative Expenses for OCX have been equal to 732.85% of Gross Profit Margin.
-
The Research & Development expenses have been 523.07% of Revenue.
-
The Net Earning history of OCX is -3,225.04% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 4 years.
OncoCyte Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | OCX |
| CUSIP: | 68235C |
| Website: | oncocyte.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 1.62 |
| Quick Ratio: | 1.41 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |